CD274 and cancer: Enhancing the immune response against cancer cells, particularly in the case of adverse events—called immune-related adverse events (irAEs)—resulting from immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, should be a primary focus [42].